🕒 Created · Updated

Revolution Medicines' New Drug Daraxonrasib Shows Promise for Advanced Lung Cancer Treatment

Revolution Medicines has developed a new oral RAS inhibitor therapy called daraxonrasib, which has shown promising results in treating advanced RAS-mutant non-small cell lung cancer (NSCLC). In a Phase 1/2 trial published in the New England Journal of Medicine, researchers found that the drug reduced tumor burden in more than 30% of patients who had previously tried other therapies with little success. For the most clinically relevant subgroup of 38 patients treated with 160-220 mg of daraxonrasib, the objective response rate was 42% with a median overall survival of 16 months. These patients had previously received platinum-based chemotherapy and immunotherapy but had not yet received docetaxel. The drug was recently approved by the Food and Drug Administration for treating metastatic pancreatic adenocarcinoma. In a late-stage clinical trial, daraxonrasib nearly doubled the median overall survival compared to standard chemotherapy. While most patients experienced side effects such as rash, diarrhea, and nausea, the results were considered manageable compared to existing alternatives. The Food and Drug Administration will likely request further late-stage clinical trials before evaluating the drug's potential for approval as a treatment for lung cancer.

Sources

Paywall and unreadable sources